Vivos Therapeutics (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (“OSA”) in adults), plans to release its second quarter 2024 financial results after market close today, Wednesday, August 14, 2024. In addition, the company’s management will host a conference at 5 p.m. ET to review the results and provide an overview of Vivos’ recent achievements and developments. Interested participants can …
